Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.The Leukemia & Lymphoma Society (LLS) is to support clinical development of Ascenta Therapeutics' oral small molecule inhibitor of IAPs (inhibitor of apoptosis proteins), AT-406, for patients with acute myeloid leukemia (AML), under an agreement signed between the two organisations.
Subscribe to our email newsletter
As per the agreement, Ascenta will conduct its first Phase I trial of AT-406 in adults with AML in combination with the standard AML induction regimen, and expects to start patient enrollment in this study in the first quarter of 2011 in the US.
LLS will also support the investigation of biomarkers for AT-406 for this disease.
LLS executive vice president and chief mission officer Louis DeGennaro said their work with Ascenta will not only determine if their oral multi-IAP inhibitor shows promise in patients with AML but also help identify which of these patients might receive the most benefit.